Corrigendum: “Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)” (Annals of Oncology (2020) 31(1) (79–87), (S0923753419354055), (10.1016/j.annonc.2019.09.004))
M. Kundranda, A. C. Gracian, S. F. Zafar, E. Meiri, J. Bendell, H. Algül, F. Rivera, E. R. Ahn, D. Watkins, U. Pelzer, V. Charu, A. Zalutskaya, G. Kuesters, J. M. Pipas, S. Santillana, V. Askoxylakis, A. H. Ko
Research output: Contribution to journal › Comment/debate
1Scopus
citations
Fingerprint
Dive into the research topics of 'Corrigendum: “Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)” (Annals of Oncology (2020) 31(1) (79–87), (S0923753419354055), (10.1016/j.annonc.2019.09.004))'. Together they form a unique fingerprint.